You have 9 free searches left this month | for more free features.

CD30 CAR

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Germ Cell Tumor, Nonseminomatous Germ Cell Tumor Trial in Chapel Hill (ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine)

Recruiting
  • Germ Cell Tumor
  • Nonseminomatous Germ Cell Tumor
  • ATLCAR.CD30 Cells
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 13, 2022

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

Recruiting
  • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
  • Classical Hodgkin Lymphoma
  • CD30.CAR-EBVST cells
  • Houston, Texas
  • +1 more
Jul 20, 2022

Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

Recruiting
  • Lymphoma
  • +7 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022

Lymphoma, Relapse/Recurrence Trial in Wuhan, Nanchang (CD30 CAR-T, Camrelizumab)

Recruiting
  • Lymphoma
  • Relapse/Recurrence
  • Wuhan, Hubei, China
  • +1 more
Apr 8, 2022

Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent Trial in United States (Nivolumab, Autologous

Recruiting
  • Classical Hodgkin Lymphoma
  • +2 more
  • Duarte, California
  • +4 more
Jun 27, 2022

Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory Trial in United States (CD30.CAR-T, Fludarabine,

Active, not recruiting
  • Hodgkin Lymphoma, Adult
  • +3 more
  • Duarte, California
  • +4 more
Apr 3, 2022

Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified Trial in Hangzhou (Anti CD30 CAR-T Cell Injection)

Not yet recruiting
  • Hodgkin Lymphoma
  • +7 more
  • Anti CD30 CAR-T Cell Injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of medicine, Zhejiang Uni
Jan 12, 2022

Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)

Recruiting
  • Peripheral T Cell Lymphoma
  • ATLCAR.CD30 T cells
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
Mar 4, 2022

Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 13, 2023

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Hodgkin Lymphoma, Adult Trial in Chapel Hill (ATLCAR.CD30, Bendamustine, Fludarabine)

No longer available
  • Hodgkin Lymphoma, Adult
  • ATLCAR.CD30
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2021

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Houston (autologous CAR.CD30 EBV specific-CTLs)

Active, not recruiting
  • Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • autologous CAR.CD30 EBV specific-CTLs
  • Houston, Texas
  • +1 more
Feb 4, 2022

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Trial in Chapel Hill, Houston (CAR.CD30 T cells)

Active, not recruiting
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Lymphoma
  • CAR.CD30 T cells
  • Chapel Hill, North Carolina
  • +2 more
Mar 16, 2022

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 cells)

Active, not recruiting
  • Hodgkin Disease
  • +8 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
  • +1 more
Mar 2, 2022

Hodgkin Lymphoma, Adult, T Cell Lymphoma Trial in Barcelona (HSP-CAR30)

Recruiting
  • Hodgkin Lymphoma, Adult
  • T Cell Lymphoma
  • HSP-CAR30
  • Barcelona, Spain
    Hospital Santa Creu i Sant Pau
Nov 30, 2020

Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Lymphoma
  • CD70-targeting CAR-T cells
  • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 9, 2023

Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Solid Tumor, Adult
  • CD70-targeting CAR-T cells
  • Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 8, 2023

Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma Trial in San Francisco (Fludarabine, Cyclophosphamide,

Recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +8 more
  • San Francisco, California
    University of California, San Francisco
May 2, 2022

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)

Recruiting
  • B-Cell Non Hodgkin Lymphoma
  • B-Cell Acute Lymphoblastic Leukemia
  • anti-CD19 CAR T-cells
  • Hanoi, Vietnam
    Vinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023